Skip to main content

RLMD

Stock

RLMD

Stock
Health Care
Biotechnology

Performance overview

RLMD Price
Price Chart

Forward-looking statistics

Beta
1.02
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Company info

SectorHealth Care
IndustryBiotechnology
Employees23
Market cap$89.0M

Fundamentals

Enterprise value-$7.1M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.51
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$344K
Avg trading volume (10 day)$274K
Put-call ratio—

Macro factor sensitivity

Growth-3.0
Credit+8.5
Liquidity+0.1
Inflation-5.0
Commodities-0.1
Interest Rates-1.1

Valuation

Dividend yield0.00%
PEG Ratio-0.31
Price to sales—
P/E Ratio-0.31
Enterprise Value to Revenue—
Price to book0.93

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

On Wednesday, Relmada Therapeutics, Inc. RLMD announced a preplanned interim analysis of the Reliance II Phase 3 study.

Benzinga (December 4, 2024)
Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research (August 12, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free